Researchers have devised a simple new test that will help clinicians decide whether to use oral or intravenous (IV) antibiotics to treat childhood infections.
According to a team from the Murdoch Children's Research Institute (MCRI) in Melbourne, Australia, clinicians often face a difficult choice in how best to treat childhood infections where antibiotics are needed.
"Using IV antibiotics when they're not needed means unnecessary hospitalisations, risk of complications and a financial burden on families and hospitals," said lead author Laila Ibrahim, a doctoral student at MCRI.
"Using oral antibiotics when IV is required risks children becoming more unwell, hence the need to standardise the decision between the two when treating childhood infections," she added.
Developed and validated in children attending The Royal Children's Hospital with a common skin infection, the Melbourne ASSET Risk Score is the first clinical risk score to help clinicians decide between IV and oral antibiotics in children.
The findings are published in the journal Pediatrics.
The team developed the risk score with 285 children aged six months to 18 years having cellulitis -- a common skin infection for which the choice between oral and IV antibiotics is unclear.
Using a score out of seven, with four being the cut-off for IV use, the assessment examines the child's risk of sepsis, hand size, swelling, eyes and muscle tenderness.
While developed for cellulitis, the researchers said the risk score, which uses features that can be observed in the child and no extra invasive tests, could be adapted for other settings and different childhood infections.
The next step will be testing the assessment in children at other hospitals.
--IANS
rt/nir
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
